Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Multi-center, Open Label, Dose Escalation Study of WNT974, LGX818 and Cetuximab in Patients With BRAFV600-mutant KRAS Wild-type Metastatic Colorectal Cancer Harboring Wnt Pathway Mutations

NCT02278133 is registered in ClinicalTrials.gov with Array BioPharma as lead sponsor.

NCT NCT02278133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02278133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Multi-center, Open Label, Dose Escalation Study of WNT974, LGX818 and Cetuximab in Patients With BRAFV600-mutant KRAS Wild-type Metastatic Colorectal Cancer Harboring Wnt Pathway Mutations
Lead sponsor
Array BioPharma
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2014
Completion date
June 23, 2017
Enrollment
20 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer